image: Launch of the Gustave Roussy Prize to honor a researcher whose scientific discoveries have significantly impacted cancer patient care
Credit: Gustave Roussy and Yan pei ming
To mark the 150th anniversary of its founder’s birth and the upcoming centennial of the Institute that bears his name, Gustave Roussy is proud to announce the launch of the Gustave Roussy Prize. This exceptional annual award aims to recognize a researcher whose scientific discoveries have significantly impacted cancer patient care.
A visionary physician and renowned scientist, Professor Gustave Roussy revolutionized cancer care by establishing the first consultation dedicated to cancer patients in 1921. The newly launched Gustave Roussy Prize embodies the commitment of the Institute he founded, now focused on personalized approaches to better prevent, challenge prognoses, reduce side effects, and enhance the quality and length of life for every patient.
Supported by Pierre Fabre Laboratories as founding sponsor, the Gustave Roussy Prize is endowed with €200,000 annually. It will honor a leading figure in oncology research whose discoveries have significantly improved cancer patient care. This award ranks among the most generous distinctions worldwide in the field of cancer research.
“We are very proud to support this new award. We are committed to encouraging Gustave Roussy’s initiatives as Europe’s leading cancer center, recognized for its multidisciplinary expertise and aligned with our purpose: every time we care for a single person, we make the world better. This award also extends the numerous development collaborations we have shared with Gustave Roussy over the past 25 years,” says Éric Ducournau, CEO of Pierre Fabre Laboratories.
“The Gustave Roussy Prize embodies our unwavering commitment to scientific innovation, which is essential to pushing the boundaries of oncology and offering patients increasingly effective and personalized treatments. By honoring researchers whose discoveries transform the lives of patients, we celebrate the forward-thinking vision of our founder and reaffirm our determination to cure cancer in the 21st century,” ads Professor Fabrice Barlesi, CEO of Gustave Roussy.
An Award Aligned with Contemporary Medical Challenges
The Gustave Roussy Prize is designed to honor individuals behind scientific breakthroughs with tangible benefits for cancer patients. It is open to internationally renowned researchers whose work significantly advances the treatment, understanding, or prevention of cancers.
For this inaugural edition of the Gustave Roussy Prize, applications must be submitted by December 20, 2024, at the following link: https://forms.office.com/e/rBSaqphxwG.
Award Ceremony on February 4, 2025
The winner will be selected by a jury of international experts, independent of Gustave Roussy, who will evaluate the applications based on the impact of the researcher’s work on patients. For this first edition, the Gustave Roussy Prize ceremony will be held on February 4, 2025, coinciding with World Cancer Day.
This prestigious award reflects the Institute’s dedication and the enduring vision of Professor Gustave Roussy by placing research at the service of patients and encouraging researchers to continue their vital efforts in the fight against cancer.
Background on Gustave Roussy
Ranked as the leading French and European Cancer Centre and fourth in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: 40% of patients treated are included in clinical studies.